Carboplatin in advanced hormone refractory prostatic cancer patients

Luciano Canobbio, Domenico Guarneri, Loredana Miglietta, Andrea Decensi, Francesco Oneto, Francesco Boccardo

Research output: Contribution to journalArticle

Abstract

25 patients with measurable or evaluable metastatic prostate cancer, progressive after hormonal treatment, were treated weekly with carboplatin 150 mg/m2 intravenously. The weekly schedule allowed higher dose intensity carboplatin administration with respect to the common monthly cycles. Toxicity was manageable even in elderly patients with extensive bone metastases and consisted primarily of myelosuppression. 4 out of 24 evaluable patients (17%) had a partial response and 12 (50%) had disease stabilisation. The median response duration was 7 months. Prostate-specific antigen and prostatic acid phosphatase serial values showed a correlation with disease response in only 47 and 50% of patients, respectively. There results suggest that carboplatin possesses a moderate but definite activity in prostate cancer patients.

Original languageEnglish
Pages (from-to)2094-2096
Number of pages3
JournalEuropean Journal of Cancer
Volume29
Issue number15
DOIs
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Carboplatin in advanced hormone refractory prostatic cancer patients'. Together they form a unique fingerprint.

  • Cite this